Correspondence and requests for reprints should be addressed to Yet H. Khor, B.Med.Sci., M.B. B.S., Ph.D., Respiratory Research@Alfred, School of Translational Medicine, Monash University, Level 6, The Alfred Centre, 99 Commercial Road, Melbourne, 3004 VIC, Australia. E-mail: [email protected].
*Co-senior authors.
†Deceased.
This Official Research Statement of the American Thoracic Society was approved September 2024
A data supplement for this article is available via the Supplements tab at the top of the online article.
Originally Published in Press as DOI: 10.1164/rccm.202410-2080ST on November 25, 2024
Subcommittee Disclosures: Y.H.K. served in a leadership role for the European Respiratory Society and the Thoracic Society of Australia and New Zealand; and received research support from Air Liquide Healthcare, Austin Medical Research Foundation, Lung Foundation Australia/Thoracic Society of Australia and New Zealand, MRFF, NHMRC, and RACP. R.G.B. is an employee of the U.S. Department of Veterans Affairs; served on an advisory board and received travel support from Chiesi; served as a consultant for 2nd MD, the American College of Physicians/DynaMed, Chiesi, and Theravance; provided expert panel testimony for Anesi Ozmon; received honoraria from Optum, Pri-Med, and UCLA; and received research support from the National Center for Advancing Translational Sciences, NIH/NCATS, NIH/NHLBI, Respiratory Health Association, and VA/HSR&D. J.D.C. served as a consultant for Antabio, AstraZeneca, Boehringer Ingelheim, Genentech, Insmed, and Zambon; and received research support from AstraZeneca, Boehringer Ingelheim, Genentech, Gilead Sciences, GlaxoSmithKline, Grifols, Insmed, Novartis, and Trudell. H.C. received honoraria from Abbott, Boryung Pharmaceuticals, and Kolon Pharmaceuticals; and received research support from the Korean Ministry of Education. V.S.F. is an employee of and received research support from the U.S. Department of Veterans Affairs; served as a consultant for NIH; served on a data safety and monitoring board for the NIH and the U.S. Department of Veterans Affairs; and served as a speaker for MetroHealth. M.G. served as a consultant for AstraZeneca, Genentech, Insmed, Regeneron, and Teva; and received honoraria from AstraZeneca, Genentech, and Regeneron. A.E.H. served in a leadership role for the Thoracic Society of Australia and New Zealand. H.P. served in a leadership role for the European Respiratory Society; received research support from Asthma UK, Horizon Europe, MRC Applied Global, and NIHR; and served as a speaker for Sandoz and Teva. C.J.R. served as a consultant for AstraZeneca, Boehringer Ingelheim, Hoffmann-La Roche, Trevi Therapeutics, and Veracyte; served as an expert witness and received travel support from Boehringer Ingelheim; received honoraria from AstraZeneca, Boehringer Ingelheim, Cipla, Hoffmann-La Roche, Pliant Therapeutics, Trevi Therapeutics, and Veracyte; and received research support from Boehringer Ingelheim, Hoffmann-La Roche, and VIDA Diagnostics. K.I.A. served on an advisory board for PF Warriors; received research support from the American Lung Association, Community IDC (NIMHD), Genentech, the NIH/NHLBI, the Scleroderma Foundation, and the Stony Wold-Herbert Fund; and served on a scientific review committee for the Pulmonary Fibrosis Foundation. T.B. served on advisory boards for FluidIQ, the Pulmonary Wellness Foundation, and the Scientific Registry of Transplant Recipients Westie Foundation of America; served as a consultant for PF Warriors and Wesper; served as a fiduciary officer for FluidIQ and the Westie Foundation of America; holds a patent and received travel support from FluidIQ; received research support from Bluelight AI, PF Warriors, and Wesper; received royalties from Pulmodyne and FluidIQ; and holds stock in Bluelight AI, FluidIQ, and Latakoo. S.S.B. served as a consultant for Bellus, Boehringer Ingelheim, Merck, Nerre, and Trevi. J.B. served as a staff member for the European Lung Foundation. B.C. served on a patient advisory group for the European Lung Foundation. M.F. received research support from the NIH. T.G. is an employee of the University of Aberdeen. J.L. served as a consultant for AstraZeneca. F.J.M. served as a consultant for AstraZeneca, Boehringer Ingelheim, Biogen, Bristol Myers Squibb, Chiesi, CSL Behring, DevPro, Endeavor, Excalibur, F. Hoffmann-La Roche, GlaxoSmithKline, Lung Therapeutics/Aileron, Nitto, Novartis, Promedior/Roche, Regeneron, RS BioTherapeutics, Sanofi, Two XR, UpToDate, and Zambon; served on a data and safety monitoring board for Boehringer Ingelheim and GlaxoSmithKline; served on an endpoint review committee for Medtronic; received honoraria from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Roche; served in a leadership role for Afferent, Chiesi, Merck, Patara/Respivant, Regeneron, Roche, and Vicore; and received research support from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, NHLBI, Novartis, Polarean, Sanofi/Regeneron, Sunovion, and Teva. C.C.M. received research support from AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo; received honoraria from Boehringer Ingelheim; and served in a leadership role for the European Lung Foundation and the European Respiratory Society. A.A.P. served on advisory boards for Eli Lilly, Sanofi, and Takeda; served as a consultant for the American Academy of Asthma and Immunology, the Foundation of the American College of Allergy, Asthma, and Immunology, Food Allergy Research Education, and Northwestern Memorial Hospital; received honoraria from the American Academy of Allergy, Asthma, and Immunology, Food Allergy Research and Education, and the Wisconsin Allergy Society; served as primary investigator for the Agency for Healthcare Research and Quality; served as a co-investigator for the NIH; served in a leadership role for the Chicago Asthma Consortium; received a public policy award from the American Lung Association; received research support from the American Lung Association and the Illinois Department of Public Health/Respiratory Health Association; and received travel support from the American Academy of Pediatrics and Food Allergy Research and Education. H.W. served as a consultant for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Sanofi. M.S.W. served on an advisory board for Boehringer Ingelheim, the Dutch Lung Fibrosis and Sarcoidosis Patient Association, the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation, and F. Hoffmann-La Roche; served as a consultant for AstraZeneca, Avalyn Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Calluna, CLS Behring, F. Hoffmann-La Roche, Galapagos, Galecto, GlaxoSmithKline, Horizon Therapeutics, Kinevant Sciences, Molecure, Nerre Therapeutics, Novartis, PureTech Health, Thyron, Trevi Therapeutics, and Vicore; received honoraria from Boehringer Ingelheim, CSL Behring, F. Hoffmann-La Roche, Novartis, and Sanofi; served in a leadership role for the European Reference Network, the European Respiratory Society, and the Netherlands Respiratory Society; and received research support from AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, F. Hoffmann-La Roche, The Dutch Lung Foundation, The Dutch Pulmonary Fibrosis Organization, The Netherlands Organization for Health Research and Development, and Sarciodosis.nl; and received travel support from Boehringer Ingelheim, F. Hoffmann-La Roche, and GlaxoSmithKline. J.A.K. served on an advisory board for the COPD Foundation; served as a consultant for the American Board of Internal Medicine, the American Academy of Allergy Asthma and Immunology, the American Board of Internal Medicine, AstraZeneca, BData, CarePath, CereVu Medical, the COPD Foundation, DynaMed, Genentech, GlaxoSmithKline, Goodwin Law, Inogen, Teva, and Verona; served on a data safety monitoring board for Cambridge University Hospitals NHS Foundation Trust/University of Cambridge and the NHLBI; served as a fiduciary officer for the Global Initiative for Asthma and Respiratory Health Association; served in a leadership role for the COPD Foundation, the Global Initiative for Asthma, and the Respiratory Health Association; and received research support from the American Lung Association, the COPD Foundation, the NIH, the Patient-Centered Outcomes Research Institute, and Verily. V.P., R.A., R.B., R.F., L.H.W., U.M.K., H.O., I.S., and K.W. reported no commercial or relevant non-commercial interests from ineligible companies.
